List of Excipients in Branded Drug HYDROCORTISONE BUTYRATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	HYDROCORTISONE BUTYRATE	hydrocortisone butyrate	21695-971	BUTYLPARABEN
Rebel Distributors Corp	HYDROCORTISONE BUTYRATE	hydrocortisone butyrate	21695-971	CETETH-20
Rebel Distributors Corp	HYDROCORTISONE BUTYRATE	hydrocortisone butyrate	21695-971	CETOSTEARYL ALCOHOL
Rebel Distributors Corp	HYDROCORTISONE BUTYRATE	hydrocortisone butyrate	21695-971	CITRIC ACID MONOHYDRATE
Rebel Distributors Corp	HYDROCORTISONE BUTYRATE	hydrocortisone butyrate	21695-971	LIGHT MINERAL OIL

Generic Drugs Containing HYDROCORTISONE BUTYRATE

Company	Ingredient	NDC	Excipient
Taro Pharmaceuticals USA Inc	hydrocortisone butyrate	51672-4061	CITRIC ACID MONOHYDRATE
Taro Pharmaceuticals USA Inc	hydrocortisone butyrate	51672-4061	GLYCERIN
Taro Pharmaceuticals USA Inc	hydrocortisone butyrate	51672-4061	ISOPROPYL ALCOHOL
Taro Pharmaceuticals USA Inc	hydrocortisone butyrate	51672-4061	POVIDONE
Taro Pharmaceuticals USA Inc	hydrocortisone butyrate	51672-4061	TRISODIUM CITRATE DIHYDRATE

What are the Most Frequently-Used Excipients in HYDROCORTISONE BUTYRATE?

# Of NDCs	Excipient
7	ANHYDROUS CITRIC ACID
1	ANHYDROUS TRISODIUM CITRATE
7	BUTYLATED HYDROXYTOLUENE
8	BUTYLPARABEN
7	CETETH-20

Last updated: August 17, 2026

Hydrocortisone butyrate is a mature topical corticosteroid with limited active-ingredient exclusivity but meaningful commercial opportunity in formulation design, pediatric usability, dispensing efficiency, and channel-specific products. The strongest strategy is usually a differentiated topical vehicle rather than a simple cream generic. Opportunities include low-irritancy emulsions, preservative-optimized lotions, non-greasy ointments, metered dispensing, larger pack sizes, and products designed for chronic dermatology use.

Hydrocortisone Butyrate Excipient Strategy and Commercial Opportunities

What is hydrocortisone butyrate and how is it positioned commercially?

Hydrocortisone butyrate is a synthetic glucocorticoid used topically for corticosteroid-responsive dermatoses, including atopic dermatitis, eczema, contact dermatitis, and psoriasis. In the United States, topical products generally contain 0.1% hydrocortisone butyrate.

The molecule is commonly positioned as a medium-potency topical corticosteroid. Its commercial value comes from the balance between anti-inflammatory activity and a lower potency profile than high-potency corticosteroids such as clobetasol propionate.

Available or historically marketed dosage forms include:

Dosage form	Typical strength	Primary commercial use
Cream	0.1%	General-purpose dermatology and primary care
Ointment	0.1%	Dry, fissured, or lichenified lesions
Lotion	0.1%	Hair-bearing areas and larger surface areas
Topical solution	0.1%	Scalp and areas where low residue is preferred
Lipid-rich cream	0.1%	Atopic dermatitis and barrier-impaired skin

The reference product family has been associated with the Locoid brand, including Locoid Lipocream and other topical presentations. FDA labeling identifies hydrocortisone butyrate as a topical corticosteroid with warnings relating to systemic absorption, hypothalamic-pituitary-adrenal axis suppression, pediatric use, and application over large or occluded areas.[1]

What excipients are most important in hydrocortisone butyrate formulations?

The excipient system determines much of the product’s commercial performance. Hydrocortisone butyrate is a lipophilic corticosteroid ester, so solvent selection, oil phase composition, emulsifier balance, particle size, and skin deposition are central formulation variables.

The main excipient functions are:

Function	Common excipient categories	Commercial effect
Oil phase	Mineral oil, petrolatum, medium-chain triglycerides, esters	Occlusion, emolliency, drug partitioning
Emulsification	Nonionic surfactants, fatty alcohols, glyceryl esters	Physical stability and skin feel
Humectancy	Propylene glycol, glycerin, sorbitol	Hydration and solvent support
Solubilization	Propylene glycol, polyethylene glycols, selected glycols	Drug distribution and clarity
Thickening	Carbomers, cellulose derivatives, fatty alcohols, waxes	Rheology and dispensing
Preservation	Parabens, phenoxyethanol, sorbates, organic acids	Microbial control
Chelation	Disodium EDTA	Preservation support and metal-ion control
pH control	Citrate, phosphate, or organic acid systems	Stability and skin compatibility
Packaging protection	Airless pumps, laminated tubes, aluminum tubes	Oxidation, contamination, and dose control

A formulation should not treat excipients as interchangeable. A change from petrolatum to a lighter ester, or from propylene glycol to glycerin, can alter drug release, epidermal deposition, irritation, preservative demand, and bioequivalence performance.

Which solvents and humectants are suitable?

Propylene glycol is commercially useful because it can act as a humectant, solvent, and penetration enhancer. It is common in topical corticosteroid products, but it can cause irritation or allergic contact dermatitis in some patients, particularly when the skin barrier is compromised.

Glycerin has a favorable consumer profile and supports moisturization, but it has lower solvent capacity for hydrocortisone butyrate. A glycerin-led system may therefore require a dispersed drug phase or a co-solvent system.

Polyethylene glycol derivatives can support solubilization and emulsion formation. They require compatibility review because high levels can change tack, wash-off, and skin feel.

A practical development approach is to screen:

1. Propylene glycol-containing systems for drug solubilization and established regulatory familiarity.
2. Reduced-propylene-glycol systems for sensitive-skin positioning.
3. Glycerin and glycol combinations for moisturization and improved consumer acceptability.
4. Short-chain or medium-chain esters for lighter sensorial performance.

What formulation strategies can differentiate hydrocortisone butyrate products?

How can a cream be differentiated?

A standard cream is the most direct generic opportunity but also the most crowded. Differentiation may come from:

• Lower tack after application.
• Faster rub-in.
• Reduced whitening on skin.
• Improved spread over large areas.
• Lower sting on excoriated skin.
• Better compatibility with moisturizers.
• Reduced transfer to clothing.
• Preservative optimization.
• Packaging that improves dose consistency.

An oil-in-water cream is generally easier to accept for routine use than a highly occlusive ointment. A water-in-oil or lipid-rich cream can provide stronger barrier support but may be less attractive for daytime use.

For atopic dermatitis, a lipid-rich cream can be positioned around barrier support and reduced dryness. The product cannot claim to repair the skin barrier unless supported by appropriate clinical and regulatory evidence, but the excipient profile can improve moisturization and application experience.

What ointment technologies are commercially attractive?

Ointments remain useful for very dry or lichenified lesions because petrolatum and related hydrocarbons reduce transepidermal water loss. They are simple, robust, and often have lower preservative requirements than aqueous creams.

Commercial drawbacks include:

• Greasiness.
• Poor cosmetic acceptability.
• Clothing transfer.
• Difficult removal.
• Reduced use on large surface areas.
• Low patient adherence in daytime treatment.

A differentiated ointment could use a lower-grease hydrocarbon system, a semi-solid ester phase, or an anhydrous gel structure. The principal technical risk is preserving corticosteroid release while improving sensory properties. Excessive reduction in occlusion may reduce clinical usefulness for dry lesions.

What lotion and solution strategies offer?

Lotions and solutions are attractive for scalp disease, hair-bearing areas, and larger body surfaces. They spread rapidly and leave less residue than ointments.

The key formulation risks are:

• Stinging from alcohols or glycols.
• Drying from volatile solvents.
• Crystallization during storage.
• Inadequate drug uniformity.
• Spray or pump clogging.
• Dose variability.
• Increased microbial-control requirements for aqueous systems.

An aqueous lotion requires a robust preservative system and container-closure assessment. A hydroalcoholic solution can improve evaporation and scalp application but may be poorly tolerated on fissured or inflamed skin.

What excipient opportunities exist for pediatric hydrocortisone butyrate products?

Pediatric dermatology is a major formulation opportunity because caregivers often prioritize tolerability, low mess, ease of spreading, and predictable dosing.

A pediatric-oriented product should consider:

• Minimal fragrance and color.
• Low sensitization potential.
• Controlled preservative exposure.
• Low sting on broken skin.
• Pump or tube dispensing that limits contamination.
• Easy removal from hands.
• Clear application instructions.
• Compatibility with routine moisturizers.

FDA labeling for topical corticosteroids warns that children may absorb proportionally larger amounts through the skin and may be more susceptible to systemic toxicity.[1] That makes dosing, surface-area control, and short treatment duration commercially relevant. A product cannot reduce corticosteroid safety risks through excipients alone, but a better dispenser may reduce over-application.

Airless pumps can support hygienic dispensing and reduce repeated jar contamination. They also allow a more premium positioning, although pump compatibility with viscous creams must be tested for priming, residual volume, and dose uniformity.

What formulation patents and intellectual property protect hydrocortisone butyrate products?

The active ingredient is mature, so commercial protection is more likely to arise from formulation, process, delivery, or device claims than from basic composition-of-matter rights.

Potentially relevant claim categories include:

IP category	Typical subject matter	Competitive value
Vehicle composition	Specific oil, water, surfactant, and solvent ratios	Moderate to high if difficult to design around
Particle engineering	Micronized or controlled-size hydrocortisone butyrate	Moderate
Release profile	Controlled deposition or modified release	Moderate
Preservative system	Low-irritancy or preservative-reduced system	Low to moderate
Packaging	Metered pump, airless container, or specialized applicator	Moderate
Manufacturing process	Homogenization, cooling, crystallization, or filling process	Moderate
Method of use	Treatment of specific dermatologic conditions or patient groups	Variable
Combination product	Hydrocortisone butyrate with moisturizer or barrier-support components	Variable

Historic brand products may have had formulation patents or FDA-listed patents, but current patent status must be determined from the active Orange Book entries and relevant patent databases. A product-specific patent number or expiration date should not be assumed from the brand name alone.

For a new entrant, the most defensible IP strategy is a narrow but technically supported formulation claim set covering:

• Excipient ratios.
• Drug particle characteristics.
• Physical stability.
• Reduced crystallization.
• Improved delivery to the stratum corneum.
• Preservative reduction.
• Container-device interaction.
• Performance after repeated dispensing.

Broad claims covering a conventional hydrocortisone butyrate cream are likely to face validity and obviousness pressure because topical corticosteroid vehicles are well developed.

What is the FDA regulatory pathway for hydrocortisone butyrate products?

A conventional generic cream, ointment, lotion, or solution would normally pursue an abbreviated new drug application if it can satisfy the applicable FDA requirements for pharmaceutical equivalence and bioequivalence.

Relevant regulatory considerations include:

• Same active ingredient.
• Same strength.
• Same dosage form.
• Same route of administration.
• Comparable inactive-ingredient acceptability.
• Demonstrated product quality.
• Appropriate in vitro and, where required, in vivo bioequivalence.
• Compliance with topical product manufacturing requirements.

A materially different vehicle may require a more complex development strategy. A 505(b)(2) application could be considered where the sponsor relies partly on an existing product or published data but proposes a meaningful formulation, delivery, indication, or dosing change.

Topical corticosteroid development can require more than simple analytical comparison. FDA may evaluate comparative physicochemical properties, drug release, permeation, rheology, particle size, metamorphosis, and other product attributes. For semisolid products, product sameness is strongly influenced by microstructure and manufacturing conditions.

The FDA’s guidance on topical dermatologic products identifies in vitro release testing and other comparative methods as important tools in product development and bioequivalence assessment.[2]

What is the Orange Book status of hydrocortisone butyrate?

Hydrocortisone butyrate products approved in the United States are generally evaluated through FDA’s drug-product approval and listing systems. Orange Book status depends on the specific product, applicant, dosage form, strength, marketing status, and any listed patents or exclusivity.

For commercial diligence, the relevant review should distinguish:

1. Approved products from discontinued products.
2. Reference listed drugs from generic products.
3. Active listings from historical listings.
4. Patent listings from regulatory exclusivity.
5. Cream, ointment, lotion, and solution presentations.

A hydrocortisone butyrate product may have no meaningful remaining regulatory exclusivity even if the brand remains commercially recognized. The absence of active exclusivity does not eliminate formulation or manufacturing barriers, but it reduces the value of a basic generic launch strategy.

When does hydrocortisone butyrate lose exclusivity?

The primary active-ingredient patent estate for hydrocortisone butyrate is mature. The commercial exclusivity question therefore turns mainly on:

• Whether a specific reference product has unexpired listed patents.
• Whether a formulation patent remains enforceable.
• Whether a generic can obtain approval through the ANDA pathway.
• Whether the proposed product has a design-around vehicle.
• Whether state substitution and payer behavior favor the generic.

Paragraph IV risk is usually more relevant to a formulation-specific patent than to the hydrocortisone butyrate molecule itself. An ANDA applicant could challenge a listed patent by asserting invalidity, unenforceability, or non-infringement. A Paragraph IV notice can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework, subject to statutory conditions.[3]

Because product-specific Orange Book listings change, an exact current expiration date should be tied to a verified product entry rather than generalized across all hydrocortisone butyrate presentations.

Which companies are challenging hydrocortisone butyrate products?

The competitive field includes branded and generic topical manufacturers, contract development organizations, and dermatology-focused companies. The most likely participants are companies with existing capabilities in:

• Semisolid manufacturing.
• Topical corticosteroid development.
• ANDA filings.
• Dermatology sales forces.
• Retail and specialty-pharmacy distribution.
• Private-label and contract manufacturing.

Generic competition is likely to focus on conventional creams and ointments first because these dosage forms have established demand and familiar manufacturing platforms. Lotion, solution, and advanced lipid-rich cream products can present more attractive differentiation but require greater formulation and regulatory investment.

A company entering with a conventional cream must compete on cost, supply reliability, wholesaler access, and payer coverage. A company entering with a differentiated vehicle can support a higher price, but it must prove a measurable benefit in use, tolerability, adherence, or dispensing.

What commercial opportunities exist beyond a standard generic?

Premium dermatology formulations

A premium product can target patients who discontinue treatment because of greasiness, stinging, slow absorption, or poor cosmetic acceptability. The commercial thesis is stronger when the product improves daily use rather than simply changing inactive ingredients.

Pediatric and caregiver-focused products

A low-sting, easy-spreading cream with controlled dispensing may attract pediatric dermatology use. The product would require careful labeling and safety positioning because topical corticosteroids have age, surface-area, and duration limitations.

Scalp and hair-bearing-area products

A lotion or solution can address a practical gap between greasy ointments and irritating hydroalcoholic liquids. Pump delivery and low residue are relevant differentiators.

Large-area and body-use products

Larger tube sizes and efficient dispensing can reduce refill frequency. Packaging must control contamination and maintain dose uniformity over extended use.

International markets

Hydrocortisone butyrate products may have different brand names, strengths, regulatory classifications, and prescription requirements outside the United States. Geographic expansion requires country-specific review of:

• Approved indications.
• Corticosteroid potency classification.
• Prescription status.
• Excipient restrictions.
• Local reference products.
• Patent and data-exclusivity rules.
• Tube and labeling requirements.

Licensing and partnering

The most attractive licensing asset is usually a validated vehicle platform rather than the hydrocortisone butyrate active ingredient. Potential partners include generic companies seeking a differentiated topical product, dermatology companies with commercial infrastructure, and contract manufacturers with specialized semisolid capabilities.

A licensing package should emphasize comparative data on:

• Drug release.
• Stability.
• Skin permeation.
• Irritation.
• Rheology.
• Application time.
• Residue.
• Packaging performance.
• Manufacturing yield.

How strong is the patent estate for hydrocortisone butyrate?

The basic molecule has limited strategic patent value because it is an established corticosteroid ester. The stronger opportunities are formulation-specific and depend on whether the claimed product has measurable technical advantages.

Patent strength is highest when claims are supported by:

• Unexpected stability improvement.
• Lower irritation with maintained drug delivery.
• Superior release or deposition.
• Reduced crystallization.
• A difficult-to-reproduce microstructure.
• A specialized package-device system.
• Clinical adherence or tolerability data.

Patent strength is weaker when claims cover routine combinations of common excipients without a demonstrated technical effect. A conventional petrolatum, mineral oil, fatty alcohol, and surfactant cream is generally easier to design around than a narrowly optimized structured vehicle with reproducible performance data.

What generic launch risks exist for hydrocortisone butyrate?

The main risks are technical and commercial rather than molecule-level exclusivity.

Risk	Impact	Mitigation
Failure to match reference-product performance	ANDA delay or deficiency	Early comparative release and characterization work
Excipient-related irritation	Lower adherence and physician acceptance	Skin-tolerance screening and preservative optimization
Drug crystallization	Dose nonuniformity and reduced performance	Microscopy, thermal analysis, and long-term stability
Poor pump performance	Inconsistent dosing	Device compatibility and end-of-life testing
Low retail differentiation	Price erosion	Targeted vehicle or channel strategy
Manufacturing scale-up failure	Batch variability	Process analytical controls and robust homogenization
Patent challenge	Litigation and delayed launch	Freedom-to-operate and design-around analysis
Limited market size	Weak return on development cost	Focus on high-value dosage forms or partnerships

How does hydrocortisone butyrate compare with competing topical corticosteroids?

Product	Relative commercial position	Formulation implication
Hydrocortisone butyrate 0.1%	Medium-potency topical steroid	Broad dermatology use with vehicle differentiation
Hydrocortisone 1%	Lower-potency, often OTC or entry-level	Greater price pressure and weaker prescription differentiation
Desonide	Low-potency prescription steroid	Pediatric and sensitive-area competition
Triamcinolone acetonide	Broad medium-potency competitor	Strong generic competition across several vehicles
Mometasone furoate	Medium-to-high potency depending on dosage form	Differentiation through potency, dosing frequency, and vehicle
Fluocinonide	Higher-potency option	Less direct competition for mild-to-moderate disease
Clobetasol propionate	Super-high-potency option	Different risk-benefit and treatment positioning

Hydrocortisone butyrate is most exposed to desonide and triamcinolone acetonide in routine dermatology. Its opportunity lies in offering more anti-inflammatory activity than low-potency products while retaining a broader usability profile than very potent corticosteroids.

What revenue exposure and market scenarios should investors assess?

Revenue potential depends on the dosage form and channel, not only on active-ingredient demand.

A conventional generic cream has the largest addressable prescribing base but also the highest likelihood of price erosion. A differentiated lotion, lipid-rich cream, or device-enabled product can command better economics but may face smaller volume and higher development costs.

Three commercial scenarios are relevant:

Scenario	Product strategy	Expected economics
Commodity generic	Conventional 0.1% cream or ointment	High volume, low margin
Specialty generic	Improved lotion, solution, or low-irritancy cream	Moderate volume, better margin
Branded formulation	Protected vehicle with clinical or usability data	Lower initial volume, highest potential price

The principal revenue risk is substitution. If a product is therapeutically interchangeable and lacks a visible usability advantage, pharmacies and payers can force rapid price competition.

Key Takeaways

• Hydrocortisone butyrate is a mature topical corticosteroid, so the active ingredient alone offers limited exclusivity value.
• The strongest commercial opportunities are formulation-led: low-irritancy creams, lipid-rich vehicles, scalp lotions, non-greasy ointments, and controlled-dose packaging.
• Propylene glycol, glycerin, petrolatum, mineral oil, fatty alcohols, nonionic emulsifiers, preservatives, and rheology modifiers require systematic optimization rather than routine substitution.
• Pediatric and sensitive-skin positioning has commercial potential but requires careful control of irritation, dosing, and labeling.
• A standard cream generic is exposed to rapid price erosion. A differentiated vehicle can support better economics if it demonstrates meaningful technical or patient-use advantages.
• Patent value is likely to reside in formulation, process, microstructure, packaging, or method-of-use claims rather than basic composition-of-matter protection.
• ANDA applicants should prioritize comparative product characterization, in vitro release, stability, microstructure, and container-closure testing.
• The most credible licensing assets are validated topical delivery platforms with data showing improved performance over conventional hydrocortisone butyrate products.

Frequently Asked Questions

Can hydrocortisone butyrate be formulated without propylene glycol?

Yes. Glycerin, polyethylene glycol systems, selected esters, and dispersed drug-phase approaches can reduce or eliminate propylene glycol, but the sponsor must re-evaluate solubility, crystallization, release, irritation, and bioequivalence.

Is hydrocortisone butyrate suitable for an airless pump?

Yes, particularly for creams and lotions. The formulation must be tested for priming, dose uniformity, residual volume, microbial protection, and compatibility with the pump materials.

Which hydrocortisone butyrate dosage form has the best commercial opportunity?

A differentiated cream or lotion generally offers the best balance of market size and development feasibility. A scalp solution may be more differentiated but has greater irritation and stability risks.

Can a new hydrocortisone butyrate vehicle receive composition-of-matter patent protection?

Yes, if the vehicle claims are novel and non-obvious and the formulation provides credible technical advantages. Routine combinations of established excipients are less likely to support strong broad claims.

Does hydrocortisone butyrate have biosimilar risk?

No. Hydrocortisone butyrate is a small-molecule drug, not a biologic. Competitive risk arises from generic drug products, formulation competitors, and potentially 505(b)(2) products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Locoid Lipocream: Hydrocortisone butyrate cream, 0.1% prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2022). Aqueous film-coated tablets and topical dermatologic drug products: Product quality and equivalence considerations. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Topical dermatologic corticosteroids: Labeling and safety information. FDA, Center for Drug Evaluation and Research.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).